VIR News and Press, Vir Biotechnology Inc. From 11/03/22

Vir Biotechnology press release ( NASDAQ: VIR ): Q3 GAAP EPS of $1.30 beats by $1.37 . Revenue of $374.6M (+261.6% Y/Y) beats by $260.32M . As of September 30, 2022, excluding restricted cash, the Company had approximately $2.7B in cash, cash equivalents, inves...

- Biomedical Advanced Research and Development Authority (BARDA) awarded contract to support pandemic preparedness for influenza and other infectious diseases; initial investment of ~$55.0 million with potential total of up to $1.0 billion - - Phase 2 data from three of the Comp...

SAN FRANCISCO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting new data from its hepatitis B virus (HBV) clinical program have been accepted for presentation at the American Association for the Study of Liver Diseases ...

SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2022, on Thursday, November 3, 2022. The corporate update and finan...

– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent U.S. government award from the Biomedical Advanced Research and Development Authority supporting development of VIR-2482 &#...

Summary Pharmaceuticals and biotechnology have the best value and quality scores. Healthcare providers look undervalued relative to 11-year averages. Other healthcare industries don’t look attractive. Focus on a biotech ETF: GNOM (and why I don’t like it). ...

Summary Updated results from Part A of the phase 2 MARCH study using both VIR-2218 and VIR3434 for Hepatitis B treatment are expected in the 2nd half of 2022. Results from the ongoing phase 2 study using VIR-2218 alone as a monotherapy and in combination with PEG-IFN-a for Hepatit...

SAN FRANCISCO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head of research, is scheduled to present at the H. C. Wainwright 3 rd Annual Hepatitis B Virus...

Vir Biotechnology ( NASDAQ: VIR ) added ~10% pre-market Tuesday after the company announced a multi-year contract worth up to $1B with the U.S. government to support research efforts on infectious diseases, including influenza. The Biomedical Advanced Research and Deve...

– First award from the agency’s solicitation for contracts for Pre-Exposure Prophylaxis for Influenza – – Initial investment of approximately $55 million from Biomedical Advanced Research and Development Authority to support development of V...